Skip to main content

Bio-Rad Authorizes $250M Share Repurchase Program

NEW YORK (GenomeWeb) – Bio-Rad Laboratories said today that its board of directors has authorized a new share repurchase program, granting the company authority to repurchase up to $250 million of outstanding shares of its stock on a discretionary basis.

Repurchases may be made at management's discretion from time to time on the open market or through privately negotiated transactions, Bio-Rad said. The repurchase program has no time limit and may be suspended or discontinued at any time. Any shares acquired will be available for general corporate purposes, including supporting employee stock plans, funding acquisitions, and minimizing dilution from stock issuances. 

Bio-Rad said the new share repurchase program supersedes the company's prior share repurchase program.

"We are pleased that our balance sheet and cash flow enable us to return value to our shareholders through share repurchases as we continue to invest in internal and external opportunities," Bio-Rad President and CEO Norman Schwartz said in a statement. "Earlier this year we discussed our capital allocation approach and a share repurchase program is part of this strategy."

Earlier this month Bio-Rad reported that its third quarter revenues grew 5 percent year over year or 3 percent on a currency-neutral basis.

As of Sept. 30, Bio-Rad had $328.9 million in cash and cash equivalents.

The Scan

Response Too Slow, Cautious

A new report criticizes the global response to the threat of the COVID-19 pandemic, Nature News reports.

Pushed a Bit Later

Novavax has pushed back its timeline for filing for authorization for its SARS-CoV-2 vaccine, according to Bloomberg.

AMA Announces Anti-Racism Effort

The Associated Press reports that the American Medical Association has released a plan to address systemic racism in healthcare.

Nucleic Acids Research Papers on miRMaster 2.0, MutationTaster2021, LipidSuite

In Nucleic Acids Research this week: tool to examine small non-coding RNAs, approach to predict ramifications of DNA variants, and more.